414 related articles for article (PubMed ID: 26072027)
1. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
2. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
[TBL] [Abstract][Full Text] [Related]
3. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
[TBL] [Abstract][Full Text] [Related]
5. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
6. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
[TBL] [Abstract][Full Text] [Related]
8. A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance.
Luah YH; Sundar Raj K; Koh MBC; Linn YC
Clin Immunol; 2019 Aug; 205():83-92. PubMed ID: 31229666
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
[TBL] [Abstract][Full Text] [Related]
10. Rapid generation of CMV pp65-specific T cells for immunotherapy.
Bao L; Sun Q; Lucas KG
J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.
Meij P; Jedema I; Zandvliet ML; van der Heiden PL; van de Meent M; van Egmond HM; van Liempt E; Hoogstraten C; Kruithof S; Veld S; Marijt EW; von dem Borne PA; Lankester AC; Halkes CJ; Falkenburg JH
J Immunother; 2012 Oct; 35(8):621-8. PubMed ID: 22996368
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
14. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
Abu-Khader A; Krause S
Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
[TBL] [Abstract][Full Text] [Related]
15. CMV-specific TCR-transgenic T cells for immunotherapy.
Schub A; Schuster IG; Hammerschmidt W; Moosmann A
J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
[TBL] [Abstract][Full Text] [Related]
16. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
17. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
[TBL] [Abstract][Full Text] [Related]
18. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
20. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
